Global HIV Vaccine Enterprise annual stakeholders’ meeting: “Accelerating early phase HIV vaccine clinical research”

Consistent with its strategic objectives, the Enterprise is convening HIV vaccine R&D stakeholders with the aim to build a consensus on efficient ways to prioritize and advance vaccine product development that encompasses design, clinical testing, and funding to accelerate the development of an HIV vaccine.

17 November 2022
Download meeting report
Chair

Susan Buchbinder

Department of Epidemiology & Biostatistics, School of Medicine, University of California, San Francisco

Speakers

Kundai Chinyenze

International AIDS Vaccine Initiative, Kenya

“An overview of the pipeline of products ready to enter, or already in, early phase clinical testing”.
Barton Haynes

Barton Haynes

Duke University, USA

“Promises and challenges of new early-stage clinical testing strategies”.

Maureen Luba

Cooper Smith, Malawi

“HIV vaccine R&D in context - A community perspective: Who needs and HIV vaccine when Long-Acting PrEP is around the corner?”
Panel 1 Chair
Gavin Churchyard

Gavin Churchyard

Aurum, South Africa

Panelists (Panel 1)
Barton Haynes

Barton Haynes

Duke University, USA

Glenda Gray

Glenda Gray

South African Medical Research Council (SAMRC

Jim Kublin

Jim Kublin

HVTN, USA

Johan Vekemans

Johan Vekemans

IAVI, USA

Nandi Luthuli

Nandi Luthuli

AVAC, South Africa

Yves Levy

Professor of Clinical Immunology

Director of the Vaccine Research Institute (VRI)/Inserm (French National Institute for Health and Medical Research) University of Créteil France

What will it take to test an array of strategies to pursue answers and accelerate timelines?
Panel 2 Chair

Stacey Hannah

Director, Research Engagement

AVAC, United States

Panelists (Panel 2)
Carl Dieffenbach

Carl Dieffenbach

NIAID, USA

Carey Hwang

Industry chair

IAS CPP Vaccine Group

Margaret McCluskey

Margaret McCluskey

USAID, USA

Pervin Anklesaria

Bill & Melinda Gates Foundation (BMGF), USA

Roger Le Grand

Head of Immunology of Viral and Auto-immune Diseases

CEA, France

Supporting changing research approaches to accelerate early phase HIV vaccine R&D.
Rapporteurs
Susan Barnett

Susan Barnett

Bill & Melinda Gates Foundation, USA

Sandhya Vasan

Sandhya Vasan

MHRP, USA

William Kilembe

William Kilembe

Zambia Emory HIV Research Project, Zambia